6622 Stock Overview
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People’s Republic of China.
Zhaoke Ophthalmology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$2.65|
|52 Week High||HK$7.70|
|52 Week Low||HK$2.60|
|1 Month Change||-11.67%|
|3 Month Change||-33.75%|
|1 Year Change||-64.81%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-81.49%|
Recent News & Updates
|6622||HK Pharmaceuticals||HK Market|
Return vs Industry: 6622 underperformed the Hong Kong Pharmaceuticals industry which returned -36.6% over the past year.
Return vs Market: 6622 underperformed the Hong Kong Market which returned -28% over the past year.
|6622 Average Weekly Movement||4.4%|
|Pharmaceuticals Industry Average Movement||5.8%|
|Market Average Movement||6.4%|
|10% most volatile stocks in HK Market||12.5%|
|10% least volatile stocks in HK Market||3.1%|
Stable Share Price: 6622 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 6622's weekly volatility (4%) has been stable over the past year.
About the Company
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People’s Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited.
Zhaoke Ophthalmology Fundamentals Summary
|6622 fundamental statistics|
Is 6622 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6622 income statement (TTM)|
|Cost of Revenue||CN¥0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.56|
|Net Profit Margin||0.00%|
How did 6622 perform over the long term?See historical performance and comparison
Is 6622 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6622?
Other financial metrics that can be useful for relative valuation.
|What is 6622's n/a Ratio?|
Price to Book Ratio vs Peers
How does 6622's PB Ratio compare to its peers?
|6622 PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
2348 Dawnrays Pharmaceutical (Holdings)
2633 Jacobson Pharma
950 Lee's Pharmaceutical Holdings
6622 Zhaoke Ophthalmology
Price-To-Book vs Peers: 6622 is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (0.6x).
Price to Earnings Ratio vs Industry
How does 6622's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
Price-To-Book vs Industry: 6622 is good value based on its Price-To-Book Ratio (0.5x) compared to the Hong Kong Pharmaceuticals industry average (0.8x)
Price to Book Ratio vs Fair Ratio
What is 6622's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.5x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate 6622's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 6622 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6622 (HK$2.65) is trading below our estimate of fair value (HK$9.2)
Significantly Below Fair Value: 6622 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Zhaoke Ophthalmology forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6622 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: 6622 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 6622 is expected to become profitable in the next 3 years.
Revenue vs Market: 6622's revenue (78.9% per year) is forecast to grow faster than the Hong Kong market (9.8% per year).
High Growth Revenue: 6622's revenue (78.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6622 is forecast to be unprofitable in 3 years.
Discover growth companies
How has Zhaoke Ophthalmology performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6622 is currently unprofitable.
Growing Profit Margin: 6622 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6622 is unprofitable, and losses have increased over the past 5 years at a rate of 39.9% per year.
Accelerating Growth: Unable to compare 6622's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6622 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: 6622 has a negative Return on Equity (-12.26%), as it is currently unprofitable.
Discover strong past performing companies
How is Zhaoke Ophthalmology's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 6622's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥79.9M).
Long Term Liabilities: 6622's short term assets (CN¥2.0B) exceed its long term liabilities (CN¥29.3M).
Debt to Equity History and Analysis
Debt Level: 6622 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 6622's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6622 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6622 has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 53.2% each year.
Discover healthy companies
What is Zhaoke Ophthalmology current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Forecast Dividend Yield
Dividend Yield vs Market
|Zhaoke Ophthalmology Dividend Yield vs Market|
|Company (Zhaoke Ophthalmology)||n/a|
|Market Bottom 25% (HK)||3.0%|
|Market Top 25% (HK)||8.8%|
|Industry Average (Pharmaceuticals)||2.9%|
|Analyst forecast in 3 Years (Zhaoke Ophthalmology)||13.7%|
Notable Dividend: Unable to evaluate 6622's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6622's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6622's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6622's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6622 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Benjamin Li (59 yo)
Dr. Xiaoyi Li, also known as Benjamin, Ph D., serves as an Executive Director & Senior Adviser at Lee's Pharmaceutical Holdings Limited since April 29, 2021. He serves as the Chief Executive Officer, Chief...
Experienced Management: 6622's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: 6622's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|30 Mar 22||BuyHK$10,566,647||Vms Holdings Limited||Company||3,102,000||HK$3.41|
|01 Dec 21||BuyHK$3,941,131||Fidelity International Ltd||Company||617,500||HK$6.38|
|Owner Type||Number of Shares||Ownership Percentage|
|Sovereign Wealth Funds||71,231,200||13.1%|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Zhaoke Ophthalmology Limited's employee growth, exchange listings and data sources
- Name: Zhaoke Ophthalmology Limited
- Ticker: 6622
- Exchange: SEHK
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$1.436b
- Shares outstanding: 541.95m
- Website: https://www.zkoph.com
Number of Employees
- Zhaoke Ophthalmology Limited
- No. 1 Meide 3rd Road
- Pearl River Industrial Park
- Guangdong Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|6622||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||Apr 2021|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/29 00:00|
|End of Day Share Price||2022/09/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.